ODN 2216 |
Katalog-Nr.GC66339 |
ODN 2216 ist ein TLR9 (Toll-like Receptor 9)-Ligand oder -Agonist. ODN 2216 induziert hohe Mengen an IFN-α und IFN-β. ODN 2216 induziert IFN-⋱ durch pDC (plasmacytoide DC) und IL-12 (p40) Produktion durch DC (dendritische Zellen). ODN 2216 stimuliert IFN-γ Produktion in peripheren mononukleÄren Blutzellen (PBMC), die indirekt und vermittelt durch IFN-α/β. ODN 2216 kann NK-Zellen aktivieren und IFN-γ fÖrdern; Produktion von TCR-getriggerten CD4+-T-Zellen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 332437-00-0
Sample solution is provided at 25 µL, 10mM.
ODN?2216 is a TLR9 (toll-like receptor 9) ligand or agonist. ODN?2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4+ T cells[1][2][3][4].
ODN 2216 (6 μg/mL, 9 days) drives Th1 development of naive CD4 T cells[1].
ODN?2216 (2 μM, 15 h) significantly decreased apoptosis of thymic DC[2].
Apoptosis Analysis[2]
Cell Line: | Thymic DC, pDC |
Concentration: | 2 μM |
Incubation Time: | 15 h |
Result: | Significantly decreased apoptosis of thymic DC (23.1 ± 0.9%), and naturally induced apoptosis of thymic pDC was not decreased (72.8 ± 2.9%). |
ODN 2216 induces T-cell mediated antitumor immune response in murine vaccination models[3]
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *